Court rebuffs Actavis on Vyvanse FiercePharma A US district court judge in DC has upheld an FDA decision to grant five years of market exclusivity to Shire's ADHD drug Vyvanse (lisdexamfetamine), ... Shire: District Court Upholds FDAs Grant of 5-Year Exclusivity Wall Street Journal Actavis Loses to FDA in ADHD Drug Ruling Courthouse News Service Shire given market exclusivity for ADHD drug Drug Store News (blog) FOXBusiness  - Pharma Times all 36 news articles »

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.